Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07657143

Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma

Trachoma is caused by repeated Chlamydia trachomatis infection in the eye. Routes of infection include close person-to-person contact and contaminated clothing. In addition, the bazaar fly Musca sorbens has been implicated in transmission. These flies frequently visit the faces of children and have been found positive for C. trachomatis, which may be transferred from the body of the flies or their regurgitated or defecated material.

This study aims to give recruited healthy volunteers a safe dose of oral ivermectin. Their faeces will be collected over subsequent days to determine whether ivermectin excreted from the body results in faecal concentrations that are high enough to prevent emergence of M. sorbens developing in faeces. It will also quantify ivermectin concentrations in tears secretions and faecal samples for up to 30 days post-treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Survival of Flies Developing in Faecal Samples Bacterial Infections Bacterial Infections and Mycoses Chlamydia Infections Chlamydiaceae Infections Conjunctival Diseases Conjunctivitis Conjunctivitis, Bacterial Corneal Diseases Eye Diseases Eye Infections Eye Infections, Bacterial Gram-Negative Bacterial Infections Infections Trachoma

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

London School of Hygiene & Tropical Medicine

London, WC1E 7HT, United Kingdom

Location contact

Anna Last, PhD

PRINCIPAL_INVESTIGATOR

Robert T Jones, PhD

CONTACT

[email protected]

+447745845880

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able and willing to give fully informed consent
  • Able to understand and comply with the study procedures
  • Able to produce a stool on most days
  • Consider themselves to be in good general health
  • Aged 18 to 65 years

Exclusion criteria

  • Suspected or known to be sensitive or allergic to ivermectin
  • Women who are pregnant, nursing or intending to become pregnant
  • Aware of having any neurological disorders or recent history of seizures
  • History of travel to a region endemic for Loa loa.
  • Currently taking acenocoumarol, warfarin or levimasole

Treatment and study plan

Ivermectin

Drug

Oral dose of ivermectin (150 micrograms/kg)

Primary outcomes

  1. Musca sorbens larvae surviving to adulthood

    Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment

    The difference in the mean number of Musca sorbens larvae surviving to adulthood in faecal samples collected at each post-treatment time point compared to pre-treatment samples. The treatment effect will be estimated separately at each time point.

Secondary outcomes

  1. Concentration of ivermectin in faeces

    Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment

    The mean concentration of ivermectin in faecal samples (ng/g) and tear samples (ng/mL) at baseline and at each post-treatment time point.

  2. First oviposition event

    Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment

    The time from presentation of each faecal sample to the first oviposition event by Musca sorbens at baseline and each post-treatment time point.

  3. Behvioural response

    Time frame: Days 1, 2, 3, 4, 5, 10 and 30 post treatment

    Observed behavioural response(s) of adult female Musca sorbens when presented with faecal samples at baseline and each post-treatment time point.

  4. Adult fly survival

    Time frame: Each time pointDays 1, 2, 3, 4, 5, 10 and 30 post treatment

    The survival of adult female Musca sorbens when presented with faecal samples collected at baseline and each post-treatment time point, measured as time to death.

Sponsors and collaborators

Lead sponsor

London School of Hygiene and Tropical Medicine

Other

Registry information

Official study title

Evaluation of the Impact of Oral Ivermectin (150 Micrograms/kg) on Musca Sorbens, the Putative Vector of Trachoma

Acronym: IVERMUSC

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 18, 2026
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.